ACI 17th Annual “BIG FOUR” Pharmaceutical Pricing Boot Camp

In this session panelists discussed the VHCA calculations, from nuts and bolts to complex issues, and also provided a timely analysis of the IRA and how it “imports” the Non-FAMP into the new IRA pricing program.

The panel provided insights into:

PART I: IRA & VHCA Section 603 Interconnectedness

• Summary of IRA program and drug price negotiation / MFP
• Leveraging of Non-Federal Average Manufacturers Price (Non-FAMP)

PART II: VHCA Section 603 Non-FAMP & FCP Calculations and Reporting

• The Framework for Calculation and Reporting
• “Nuts and bolts” of the Non-FAMP and FCP calculations
• Annual and quarterly reporting requirements and their intersection with FSS contract
• Best practices for obtaining data necessary for Non-FAMP calculation
• Overlapping issues as between Medicaid (BP & AMP) and VHCA (Non-FAMP)